Xtrudane

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameXtrudane
Drug Alias Namepembrolizumab biosimilar (Xbrane Biopharma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsKidney NeoplasmsLung NeoplasmsHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesXbrane Biopharma Ab
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesXbrane Biopharma Ab
Active IndicationsN/A
Inactive IndicationsKidney NeoplasmsLung NeoplasmsHead and Neck Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A